PharmaPoint: Major Depressive Disorder - Current and Future Players
GlobalData has released its pharma report, “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
Investigation of current and future market competition for Major Depressive Disorder.
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis
Reasons to buy
Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
What’s the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize
Sales for Major Depressive Disorder (MDD)Market
GlobalData estimates the drug sales for MDD in2013 were approximately $9.3 billion across the7MM and Australia covered in this forecast. By theend of the forecast period in 2023, sales will growto approximately $9.7 billion with a CompoundAnnual Growth Rate (CAGR) of 0.39%.
GlobalData forecasts that sales for MDD will followa declining trend until 2017, dropping to $7.3billion. This decline in market value will be mainlydriven by patent expiries for Eli Lilly’s Cymbalta,Otsuka Pharmaceutical/BMS’s Abilify, andAstraZeneca’s Seroquel XR. GlobalData expectsgrowth in sales for MDD to return in 2018. Thereturn to growth will be driven by:
The increasing uptake for Lundbeck/Takeda’sBrintellix.
The introduction of four adjunctive therapiesand three other antidepressant therapiesduring the forecast period.
The increasing number of prevalent cases ofMDD.Conversely, major barriers to the growth of theMDD market include:
Intense competition from available genericproducts.